Trials / Active Not Recruiting
Active Not RecruitingNCT06062537
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Intergroupe Francophone du Myelome · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.
Conditions
Timeline
- Start date
- 2023-09-19
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-10-02
- Last updated
- 2026-04-13
Locations
31 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06062537. Inclusion in this directory is not an endorsement.